Please use this identifier to cite or link to this item: doi:10.22028/D291-37463
Volltext verfügbar? / Dokumentlieferung
Title: Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes : Results from COSYCONET
Author(s): Kahnert, Kathrin
Jörres, Rudolf A.
Lucke, Tanja
Trudzinski, Franziska C.
Mertsch, Pontus
Bickert, Christiane
Ficker, Joachim H.
Behr, Jürgen
Bals, Robert
Watz, Henrik
Welte, Tobias
Vogelmeier, Claus F.
Alter, Peter
Language: English
Title: International Journal of Chronic Obstructive Pulmonary Disease
Volume: 2021
Issue: 16
Pages: 3189-3199
Publisher/Platform: DOVE
Year of Publication: 2021
Free key words: chronic obstructive pulmonary disease
oral corticosteroids
inhaled corticosteroids
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Background: Patients with chronic obstructive pulmonary disease (COPD) often have osteoporosis and diabetes as comorbid conditions. Anti-diabetic medication, including metformin, has protective effects on osteoporosis in experimental studies. We therefore studied whether patients with COPD receiving anti-diabetic medication had a lower osteoporosis prevalence in a large COPD cohort, COSYCONET. Methods: Assessment of osteoporosis was based on patients’ reports of physician-based diagnoses and the presence of disease-specific medication. The predictive value of physical characteristics, lung function, comorbidities, cardiovascular medication, and the use of antiinflammatory diabetes medication, including metformin, sulfonylureas, glinides or DPP4I, was evaluated using logistic regression analysis. NCT01245933. Results: In total, 2222 patients were eligible for analysis (863 [39%] female, mean age 65 y), 515 of whom had higher symptoms and exacerbations (Global Initiative for Chronic Obstructive Lung Disease group D). Osteoporosis was present in 15.8% of the overall cohort, and in 24.1% of GOLD D patients. Regression analyses identified the following as associated with osteoporosis (p < 0.05): female sex, higher age, lower body-mass index, asthma, higher air trapping, oral steroids, and cardiovascular medication. Although oral anti-diabetic medication was overall not associated with a lower prevalence of osteoporosis (p = 0.131), anti-inflammatory anti-diabetic medication (p = 0.009) and metformincontaining therapy (p = 0.039) were. This was driven by GOLD D patients. Conclusion: In a large COPD cohort, anti-inflammatory diabetes therapy, including metformin, was associated with a lower prevalence of osteoporosis, especially in patients with higher symptoms and exacerbations. These findings suggest a protective effect of common antidiabetic medication on osteoporosis, possibly as a result of attenuated systemic inflammation.
DOI of the first publication: 10.2147/COPD.S335029
URL of the first publication:
Link to this record: urn:nbn:de:bsz:291--ds-374630
ISSN: 1178-2005
Date of registration: 30-Sep-2022
Faculty: M - Medizinische Fakultät
Department: M - Innere Medizin
Professorship: M - Prof. Dr. Robert Bals
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
There are no files associated with this item.

Items in SciDok are protected by copyright, with all rights reserved, unless otherwise indicated.